Home » Topics » Gastrointestinal, BioWorld Science

Gastrointestinal, BioWorld Science
RSS

Adalimumab promotes clinical remission in moderate to severe Crohn's disease

Sep. 29, 2004

Promising results with small molecule MIF inhibitors in a preclinical model of colitis

Sep. 27, 2004

EMZ-702 enters clinical development for hepatitis C

Sep. 21, 2004

BioMimic formed to develop human applications of Receptor Mimic Technology

Sep. 21, 2004

Nexium completes European mutual recognition procedure for new indications

Sep. 20, 2004

First two cohorts enrolled in phase II study of ANA-380 for HBV

Sep. 17, 2004

Promising triterpenoid derivative for the treatment of IBD

Sep. 17, 2004

TheraCLEC selected for CMA Pilot 2 program

Sep. 15, 2004

Phase III study of INKP-102 commences enrollment

Sep. 13, 2004

Entereg NDA accepted for review

Sep. 13, 2004

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 26, 2026.
Brain-computer interfaces are here but long road ahead
BioWorld
The field of BCI is continually evolving; as such, companies are increasingly highlighting the potential of their technologies to transform care. For advanced...
ENCALS 2026: From genetics to advancing strategies against ALS
BioWorld Science
Amyotrophic lateral sclerosis (ALS)-associated genes provide direct therapeutic targets and reveal pathways that can be used to develop treatments that counteract...
Next wave of BCI firms builds on pioneers to tackle challenges
BioWorld
With the pace of neurotechnology development accelerating, a wave of brain-computer interface (BCI) companies is emerging on the heels of the pioneers. In the...
Boehringer Ingelheim identifies new mGlu3 receptor agonists
BioWorld Science
Boehringer Ingelheim Pharma GmbH & Co. KG and Vanderbilt University have discovered new dihydrobenzoxazine compounds acting as metabotropic glutamate mGlu3...